Argenx Surges on Clinical Catalysts as $0.4 Billion Volume Ranks 264th Amid FDA Label Expansion Push

On September 4, 2025, argenx (ARGX) surged 1.61% with a trading volume of $0.4 billion, ranking 264th in market activity. The stock’s performance was driven by multiple catalysts, including clinical and strategic updates.

Positive topline results from the ADAPT SERON trial of VYVGART in AChR-Ab seronegative generalized myasthenia gravis (gMG) reinforced investor confidence. The study met its primary endpoint, demonstrating statistically significant improvements across all subtypes. This success positions argenx to seek FDA label expansion for the drug, broadening its market reach.

Analysts highlighted additional momentum from argenx’s pipeline. A planned R&D webinar on September 16 will showcase ARGX-119, underscoring the company’s focus on innovation. Leadership stability was also noted, with Anant Murthy appointed as Chief Operating Officer, signaling strengthened operational capabilities.

The backtest results of the ADAPT SERON study confirmed its robustness, showing a p-value of 0.0068 and clinically meaningful improvements in disease activity across all three subtypes—MuSK+, LRP4+, and triple seronegative. These findings support the drug’s potential to address a larger patient population, reinforcing long-term growth prospects.